PNQ 103
Alternative Names: PNQ-103Latest Information Update: 28 Jul 2024
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antianaemics; Antiasthmatics; Antifibrotics; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic asthma; Pulmonary fibrosis; Sickle cell anaemia
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Allergic-asthma in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in India (PO)